Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment
Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...
Fosun Kite Biotechnology
Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co.,...
Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan
US immunotherapy specialist Kite Pharma, Inc. has announced that the Marketing Authorization for Yescarta (axicabtagene...
Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers
China-based conglomerate Shanghai Fosun High Technology (Group) Co., Ltd has entered into a partnership with...
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...
Fosun Kite’s CAR-T Therapy FKC889 Approved for Clinical Trials in China
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its...
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion)...
Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...